Tests vericiguat in heart failure after a recent heart attack
Tests the drug vericiguat in adults with heart failure after a heart attack.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
Key facts
- Where
- Chongqing, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who developed acute heart failure within 14 days in hospital after a heart attack (STEMI or NSTEMI) and had the blocked artery treated. It tests vericiguat.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute heart failure within 14 days in hospital after STEMI or NSTEMI, with typical symptoms or signs, a need for diuretics, LVEF 45% or lower on echocardiography, and raised NT proBNP.
- Earlier treatment
- The blocked (criminal) coronary artery must have been treated by revascularization during the hospital stay.
- Biomarker or test result
- NT proBNP of 1000pg/ml or more with sinus rhythm, or 1600pg/ml or more with atrial fibrillation/flutter. eGFR of 15 ml/min/1.73m2 or more.
Main reasons for not taking part
- Staged revascularization planned, or the culprit artery was not successfully opened
- Severe uncontrolled lung disease
- Severe liver or kidney dysfunction (Child Pugh grade C or eGFR below 15ml/min/1.73m2)
- Allergy to vericiguat or to heart failure medicines such as ACEI, ARB, ARNI, beta blockers, SGLT2i, MRA
- Symptomatic low blood pressure or systolic blood pressure below 90mmHg
Read by machine on 9 November 2026.
Where in China
- The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Dongying Zhang
- Trial code
- NCT06812546
- Record updated
- 6 February 2025
- Original description
Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart failure after acute myocardial infarction. So we conducted this multi-center, prospective, cohort study to estimate the efficacy and safety of vericiguat in HF patients after acute myocardial infarction.Read full original descriptionShow less
Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart failure after acute myocardial infarction. So we conducted this multi-center, prospective, cohort study to estimate the efficacy and safety of vericiguat in HF patients after acute myocardial infarction.
Inclusion: Age ≥ 18 years old; Undertaking revascularization for criminal coronary artery during hospitalization; Acute heart failure occurs within 14 days in hospital after STEMI or NSTEMI, meeting all of the following criteria: typical symptoms or signs of heart failure; Treatment with oral or intravenous diuretics is required; LVEF measured by echocardiography is ≤ 45%; Elevated levels of NT proBNP in patients with sinus rhythm ≥ 1000pg/ml and atrial fibrillation/flutter ≥ 1600pg/ml; eGFR ≥ 15 ml/min/1.73m2; Informed consent has to be given in written form.
Exclusion: Symptomatic hypotension or systolic blood pressure less than 90mmHg after discontinuing intravenous medication; Patients planning to undergo elective surgical treatment or tumor chemotherapy; Previous diagnosis of cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, etc; Severe and uncontrolled lung diseases, such as newly developed pulmonary embolism, primary pulmonary hypertension, acute exacerbation of COPD, etc; Allergies to ACEI, ARB, ARNI, beta blockers, SGLT2i, MRA, Vericiguat, and other medications; Diagnosed as Takotsubo cardiomyopathy or nonobstructive acute myocardial infarction (MINOCA); Autoimmune disease or infectious diseases with typical cardiovascular damage, such as syphilis, systemic lupus erythematosus, etc; Diagnosed with severe heart valve disease; Severe liver and kidney dysfunction, Child Pugh grade C or eGFR < 15ml/min/1.73m2; Plan to undergo staged revascularization or if the criminal coronary artery has not been successfully opened; Women in the perinatal period or those planning to conceive.